Summary

Persistence Market Research has recently released a detailed report on the China Lung Cancer Screening Market for the period 2025–2032. This in-depth analysis explores key market dynamics, including growth drivers, challenges, opportunities, and competitive insights, providing a comprehensive view of the opportunities and trends shaping early lung cancer detection in China.

Key Insights:

• China Lung Cancer Screening Market Size (2025E): USD 616.2 Million
• Projected Market Value (2032F): USD 1,295.5 Million
• Global Market Growth Rate (CAGR 2025 to 2032): ~11.2 %

Scope of the Report: China Lung Cancer Screening Market

Lung cancer continues to be one of the deadliest malignancies in China, with hundreds of thousands of deaths annually and a large proportion of cases diagnosed at late stages when treatment outcomes are poor. Early detection through systematic screening can significantly improve survival rates and reduce healthcare burdens. The China Lung Cancer Screening Market report assesses market size, segmentation by cancer type, diagnostic methods (such as low-dose spiral CT scans and chest X-rays), end-use segments (hospitals, diagnostic centers, clinics), and provincial trends across the country.

The report sheds light on a market driven by both public health initiatives and technological innovation. Key screening modalities-especially low-dose computed tomography (LDCT)-are gaining traction as standard early-detection tools. Regional market variations, driven by differing lung cancer incidence and healthcare infrastructure, are also analyzed to provide a deep understanding of local opportunities.

Market Growth Drivers:

Several important factors are fueling growth in the China lung cancer screening market:

High Lung Cancer Burden:
Lung cancer remains one of the most common cancers in China, with a significant number of new diagnoses each year-many of which occur at advanced stages. This heavy disease burden underscores the urgent need for effective screening programs to detect disease earlier and improve patient outcomes.

Government-Backed Screening Initiatives:
National and regional public health programs, such as China’s National Cancer Screening Program (NCSP), have integrated lung cancer screening into standard public health services. These guidelines encourage the use of LDCT for high-risk populations and include pilot studies and provincial rollouts that broaden screening access.

Technological Advancements:
Advances in imaging technology-particularly LDCT-offer high-resolution, low-radiation detection. AI-enhanced diagnostic tools are increasingly being deployed in clinical settings to improve accuracy and reduce radiologist workload, offering faster and more sensitive lung nodule detection.

Rising Health Awareness:
Growing awareness among patients and healthcare providers about the benefits of early lung cancer detection has led to increased screening participation, particularly in urban areas and among high-risk groups exposed to smoking, environmental pollutants, and occupational hazards.

Market Restraints:

Despite positive growth trajectories, the market also faces challenges:

Uneven Screening Uptake:
Participation in screening programs remains uneven across regions, with lower compliance seen in rural areas and among less educated populations. Barriers such as cost, logistical inconvenience, and low health literacy hinder widespread adoption.

Diagnostic Uncertainty:
High false-positive rates in screening, particularly with LDCT, can lead to unnecessary follow-up procedures, increasing patient anxiety and healthcare costs. Such issues may discourage repeat screening and strain medical resources.

Healthcare Infrastructure Gaps:
Variations in healthcare infrastructure between developed and underserved provinces limit consistent screening access, making it challenging to standardize national screening coverage.

Market Opportunities:

AI and Digital Integration:
Artificial intelligence (AI) shows considerable promise in enhancing diagnostic accuracy and workflow efficiency. AI-assisted LDCT analysis has demonstrated high accuracy in detecting lung nodules, offering opportunities for widespread deployment across screening programs.

Expansion in Rural Regions:
Increasing investments in healthcare infrastructure and awareness campaigns in under-served rural regions open new avenues for market growth by improving equitable access to screening services.

Diversified Screening Strategies:
The development of tailored screening protocols for non-smoking populations-as China has a significant proportion of lung cancer cases among non-smokers-presents opportunities to refine screening criteria and broaden target populations.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the China Lung Cancer Screening Market?
• Which diagnostic methods and technologies are gaining prominence in early detection?
• How do provincial variations affect market development across China?
• Who are the leading technology and imaging companies operating in this market?
• What are the emerging trends and future prospects for lung cancer screening adoption?

Competitive Intelligence and Business Strategy:

Key global and domestic players are actively participating in the China lung cancer screening market by supplying cutting-edge imaging technologies and AI diagnostic solutions. Companies such as Biodesix, GE HealthCare, DELFI Diagnostics, Inc., Siemens Healthineers AG, CANON MEDICAL SYSTEMS CORPORATION, Philips N.V., Medtronic plc, and Shanghai United Imaging Healthcare Co., Ltd. are prominent contributors.

These players emphasize innovation, partnerships with healthcare institutions, and localized service models to expand screening infrastructure. Strategic alliances with provincial health authorities and investments in training and tele-radiology platforms help improve diagnostic accuracy and scalability.

Key Companies Profiled:

• Biodesix
• GE HealthCare
• DELFI Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthineers AG
• Medtronic plc
• Koninklijke Philips N.V.
• Freenome Holdings, Inc.
• Shanghai United Imaging Healthcare Co., Ltd.

Key Segments Covered in China Lung Cancer Screening Industry Research

By Cancer Type:
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Diagnosis:
• Low Dose Spiral CT Scan
• Chest X-ray

By End-use:
• Hospitals and Clinics
• Diagnostic Centers
• Others

By Province:
• Shandong
• Jiangsu
• Guangdong
• Anhui
• Guizhou
• Others

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. China Lung Cancer Screening Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-economic Factors
2.3.1. China’s Healthcare Expenditure and GDP Growth Trends
2.3.2. Government Initiatives and National Screening Programs
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Value Chain Analysis
3.3. PESTLE Analysis
3.4. Porter’s Five Force Analysis
4. Price Trend Analysis 2019 - 2032
4.1. Key Highlights
4.2. Key Factors Impacting Diagnosis Costs
4.3. Pricing Analysis by Cancer Type
5. China Lung Cancer Screening Market Outlook
5.1. China Lung Cancer Screening Market Outlook: Cancer Type
5.1.1. Introduction / Key Findings
5.1.2. Historical Market Sales Area (US$ Mn) and Analysis, By Cancer Type, 2019-2024
5.1.3. Current Market Sales Area (US$ Mn) and Analysis and Forecast, By Cancer Type, 2025-2032
5.1.3.1. Non-small Cell Lung Cancer (NSCLC)
5.1.3.2. Small Cell Lung Cancer (SCLC)
5.2. Market Attractiveness Analysis: Cancer Type
5.3. China Lung Cancer Screening Market Outlook: Diagnosis
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Sales Area (US$ Mn) Analysis, By Diagnosis, 2019-2024
5.3.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Diagnosis, 2025-2032
5.3.3.1. Low Dose Spiral CT Scan
5.3.3.2. Chest X-ray
5.4. Market Attractiveness Analysis: Diagnosis
5.5. China Lung Cancer Screening Market Outlook: End Use
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Sales Area (US$ Mn) Analysis, By Sales Area, 2019-2024
5.5.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Sales Area, 2025-2032
5.5.3.1.
5.5.3.1.1. Hospitals and Clinics
5.5.3.1.2. Diagnostic Centers
5.5.3.1.3. Others
5.6. Market Attractiveness Analysis: End Use
5.7. Market Attractiveness Analysis: Province
6. China Lung Cancer Screening Market Outlook: Province
6.1. Key Highlights
6.2. Historical Market Sales Area (US$ Mn) Analysis, By Province, 2019-2024
6.3. Current Market Sales Area (US$ Mn) Analysis and Forecast, By Province, 2025-2032
6.3.1. Anhui
6.3.2. Guizhou
6.3.3. Guangdong
6.3.4. Shandong
6.3.5. Jiangsu
6.3.6. Others
6.4. Market Attractiveness Analysis: By Province
7. Competition Landscape
7.1. Market Share Analysis, 2023
7.2. Market Structure
7.2.1. Competition Intensity Mapping
7.2.2. Competition Dashboard
7.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
7.3.1. Biodesix
7.3.1.1. Overview
7.3.1.2. Solution Portfolio
7.3.1.3. Key Financials
7.3.1.4. Market Developments
7.3.1.5. Market Strategy
7.3.2. GE HealthCare
7.3.3. DELFI Diagnostics, Inc.
7.3.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7.3.5. CANON MEDICAL SYSTEMS CORPORATION
7.3.6. Siemens Healthineers AG
7.3.7. Medtronic plc
7.3.8. Koninklijke Philips N.V.
7.3.9. Freenome Holdings, Inc.
7.3.10. Shanghai United Imaging Healthcare Co., LTD.
7.3.11. Others
8. Appendix
8.1. Research Methodology
8.2. Research Assumptions
8.3. Acronyms and Abbreviations